The role of different genetic subtypes of CEBPA mutated AML

Leukemia

Volumn 28, Issue 4, 2014, Pages 794-803

  Fasan, A ^a   Haferlach, C ^a   Alpermann, T ^a   Jeromin, S ^a   Grossmann, V ^a   Eder, C ^a   Weissmann, S ^a   Dicker, F ^a   Kohlmann, A ^a   Schindela, S ^a   Kern, W ^a   Haferlach, T ^a   Schnittger, S ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

AML; CEBPA; mutation; pronosis

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; FLT3 LIGAND; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CYTOGENETICS; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NONSENSE MUTATION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CCAAT-ENHANCER-BINDING PROTEINS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PROGNOSIS;

EID: 84898051374     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.273     Document Type: Article

References (43)

1. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009; 27: 619-628.
2. Tenen DG, Hromas R, Zhang D-E. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90: 489-519. (Pubitemid 27299089)
3. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001; 27: 263-270. (Pubitemid 32201846)
4. Snaddon J, Smith ML, Neat M, Cambal-Parrales M, xon-McIver A, Arch R et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 2003; 37: 72-78. (Pubitemid 36417923)
5. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004; 4: 394-400. (Pubitemid 38579485)
6. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009; 113: 3088-3091.
7. Wouters BJ, Sanders MA, Lugthart S, Geertsma-Kleinekoort WM, van DE, Beverloo HB et al. Segmental uniparental disomy as a recurrent mechanism for homozygous CEBPA mutations in acute myeloid leukemia. Leukemia 2007; 21: 2382-2384. (Pubitemid 350011720)
8. Frohling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22: 624-633. (Pubitemid 41095065)
9. Schlenk RF, Dö hner K, Krauter J, Frohling S, Corbacioglu A, Bullinger L et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358: 1909-1918. (Pubitemid 351620111)
10. Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009; 100: 1343-1346.
11. Grossmann V, Haferlach C, Nadarajah N, Fasan A, Weissmann S, Roller A et al. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2 and GATA2 alterations impacting prognosis. Br J Haematol 2013; 161: 649-658.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
13. Arber DA, Brunning RD, Le Beau MM. Acute Myeloid Leukemia (AML) snd Related Precursor Neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC): Lyon, France, 2008, pp 110-123.
14. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
15. Haferlach T, Kern W, Schoch C, Hiddemann W, Sauerland MC. Morphologic dysplasia in acute myeloid leukemia: importance of granulocytic dysplasia. J Clin Oncol 2003; 21: 3004-3005.
16. ISCN (1995). Guidelines for Cancer Cytogenetics, Supplement to: an International System for Human Cytogenetic Nomenclature. Mitelman F, Karger S (eds). Karger: Basel, New York, 1995 17.
17. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
18. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078-3085. (Pubitemid 39517010)
19. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66. (Pubitemid 35177429)
20. Grossmann V, Roller A, Klein HU, Weissmann S, Kern W, Haferlach C et al. Robustness of amplicon deep sequencing underlines its utility in clinical applications. J Mol Diagn 2013; 15: 473-484.
21. Grossmann V, Schnittger S, Schindela S, Klein HU, Eder C, Dugas M et al. Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn 2011; 13: 129-136.
22. Kohlmann A, Martinelli G, Hofmann WK, Kronnie GT, Chiaretti S, Preudhomme C et al. The interlaboratory robustness of next-generation sequencing (IRON) study phase II: deep-sequencing analyses of hematological malignancies performed by an international network involving 26 laboratories. Blood 2012; 120: 1399.
23. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733-3739. (Pubitemid 41739006)
24. Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood 2008; 111: 2527-2537.
25. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107: 3847-3853. (Pubitemid 43726786)
26. Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, Kern W et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010; 24: 1528-1532.
27. Fasan A, Eder C, Haferlach C, Grossmann V, Kohlmann A, Dicker F et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia 2013; 27: 482-485.
28. Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia 2012; 26: 934-942.
29. Schnittger S, Haferlach C, Ulke M, Alpermann T, Kern W, Haferlach T. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010; 116: 5486-5496.
30. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039)
31. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010; 28: 2739-2747.
32. Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S et al. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann Hematol 2012; 91: 1051-1063.
33. Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005; 11: 1372-1379. (Pubitemid 40326229)
34. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia 2011; 25: 1297-1304.
35. Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, De Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717-2723.
36. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, van OS, van Putten WL, Valk PJ et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 2003; 4: 31-40. (Pubitemid 36927158)
37. Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008; 26: 5078-5087.
38. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010; 28: 570-577.
39. Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood 2011; 117: 2469-2475.
40. Dufour A, Konstandin N, Ksienzyk B, Zellmeier E, Benthaus T, Yaghmaie M et al. High frequency of GATA2 mutations in cytogenetically normal acute myeloid leukemia with biallelic cebpa mutations identified by exome sequencing. Blood 2011; 118: 72.
41. Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood 2012; 120: 395-403.
42. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H et al. TET2 mutations improve the new European Leukemia. Net risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2011; 29: 1373-1381.
43. Alpermann T, Haferlach C, Eder C, Kohlmann A, Kern W, Haferlach T et al. Sole Trisomy 8 in AML: concomitant molecular markers, stability of genetic patterns and impact on outcome. Blood 2013; 120: 2503.